Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23014937 | 1.00 | CYP1A2 (0.40) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL11533019 | 0.85 | CYP1A2 (0.39) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL18975256 | 0.80 | HSD17B10 (0.50) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL130671 | 0.80 | — | — | |
| SCHEMBL130493 | 0.80 | HSD17B10 (0.50) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL8907249 | 0.80 | HSD17B10 (0.50) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL23014965 | 0.80 | HSD17B10 (0.50) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL23014949 | 0.80 | HSD17B10 (0.50) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL135863 | 0.80 | HSD17B10 (0.50) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL2335615 | 0.80 | HSD17B10 (0.50) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360163-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2024-10-31 | — | — | US | disclosed |
| US-12049474-B2 | Nucleoside prodrugs and uses related thereto | EMORY UNIVERSITY (US) | 2024-07-30 | — | — | US | disclosed |
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2022-09-22 | — | — | US | disclosed |
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2022-09-22 | — | — | US | disclosed |
| EP-4017499-A1 | NUCLEOSIDE PRODRUGS AND USES RELATED THERETO | Emory University (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-114502172-A | Nucleoside prodrugs and related uses thereof | 爱默蕾大学 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021035214-A1 | NUCLEOSIDE PRODRUGS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | PNPO, GSTO1, CYP2C18 | CYP1A2 38/4885CYP2D6 18/4885MAPT 4429/4885 |
| US-20240360163-A1 | Nucleoside Prodrugs and Uses Related Thereto | PNPO, GSTO1, CYP2C18 | CYP1A2 38/4885CYP2D6 18/4885MAPT 4429/4885 |
| US-12049474-B2 | Nucleoside prodrugs and uses related thereto | PNPO, GSTO1, CYP2C18 | CYP1A2 38/4885CYP2D6 18/4885MAPT 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.